News

Exscientia has expanded its partnership with Bristol-Myers Squibb (BMS) to leverage artificial intelligence (AI) to discover small molecule drug candidates across oncology and immunology, among other therapeutic areas.

As part of the agreement, BMS will pay $200m upfront to Agenus, which is also eligible for up to $1.36bn in development, regulatory and commercial milestone payments and

The agreement also covers additional payments of up to $57.5m contingent on future performance. Charles River expects the deal to boost its gene therapy capabilities for viral vectors

The Central Drugs Laboratory cleared the first batch of Sputnik V doses that reached India earlier this month. Under the pilot, a soft launch has begun, and the

Besides acquiring the exclusive rights to commercialise PRG1801 in India, Dr. Reddy’s will be responsible for future development including clinical trials, in the country. Pregene will be the sole supplier

Under the terms of the deal, CD&R will pay £10.23 in cash per share in UDG. Headquartered in Dublin, UDG Healthcare provide healthcare advisory, communications, commercial, clinical and

The companies will leverage MiNA Therapeutics’ small activating RNA (saRNA) technology platform to develop the drug candidates. Using its saRNA platform, MiNA Therapeutics will research up to five

The US Food and Drug Administration (FDA) has expanded the emergency use authorisation (EUA) for Pfizer and BioNTech’s Covid-19 vaccine to include adolescents aged 12 to 15 years.

India’s Defence Research and Development Organisation (DRDO) lab Institute of Nuclear Medicine and Allied Sciences (INMAS) developed the drug in alliance with Dr Reddy’s Laboratories (DRL). The drug